Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.
Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Kirste S, Jacobasch L, Allgäuer M, Flentje M, Germer CT, Grützmann R, Hildebrandt G, Schwarzbach M, Bechstein WO, Sülberg H, Friede T, Gaedcke J, Ghadimi M, Hofheinz RD, Rödel C; German Rectal Cancer Study Group. Fokas E, et al. JAMA Oncol. 2022 Jan 1;8(1):e215445. doi: 10.1001/jamaoncol.2021.5445. Epub 2022 Jan 20. JAMA Oncol. 2022. PMID: 34792531 Free PMC article. Clinical Trial.
Interlaboratory variability of Ki67 staining in breast cancer.
Focke CM, Bürger H, van Diest PJ, Finsterbusch K, Gläser D, Korsching E, Decker T; German Breast Screening Pathology Initiative. Focke CM, et al. Eur J Cancer. 2017 Oct;84:219-227. doi: 10.1016/j.ejca.2017.07.041. Epub 2017 Aug 19. Eur J Cancer. 2017. PMID: 28829990
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
Ingold Heppner B, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmitt W, Eidtmann H, Fasching PA, Tesch H, Solbach C, Rezai M, Zahm DM, Holms F, Glados M, Krabisch P, Heck E, Ober A, Lorenz P, Diebold K, Habeck JO, Loibl S. Ingold Heppner B, et al. Among authors: habeck jo. Clin Cancer Res. 2016 Dec 1;22(23):5747-5754. doi: 10.1158/1078-0432.CCR-15-2338. Epub 2016 May 17. Clin Cancer Res. 2016. PMID: 27189162 Clinical Trial.
[A rare cause of severe gastrointestinal bleeding].
Hegedüs J, Suchner J, Binder K, Habeck JO, Ziegler T. Hegedüs J, et al. Among authors: habeck jo. Dtsch Med Wochenschr. 2016 Mar;141(6):414-7. doi: 10.1055/s-0042-100825. Epub 2016 Mar 16. Dtsch Med Wochenschr. 2016. PMID: 26983113 German.
Recurrence of malignant melanoma after 45 years.
Ziller F, Leclerque C, Bartholdt E, Habeck JO, Feldmann-Böddeker I. Ziller F, et al. Among authors: habeck jo. J Dtsch Dermatol Ges. 2015 Jan;13(1):49-51. doi: 10.1111/ddg.12431. J Dtsch Dermatol Ges. 2015. PMID: 25640495 English, German. No abstract available.
[Proposals for standardization of autopsy reports].
Wittekind C, Habeck JO, Gradistanac T. Wittekind C, et al. Among authors: habeck jo. Pathologe. 2014 Mar;35(2):182-90. doi: 10.1007/s00292-013-1885-8. Pathologe. 2014. PMID: 24619530 German.
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.
Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, Sinn BV, Ulmer HU, Kronenwett R, Just M, Kühn T, Diebold K, Untch M, Holms F, Blohmer JU, Habeck JO, Dietel M, Overkamp F, Krabisch P, von Minckwitz G, Denkert C. Issa-Nummer Y, et al. Among authors: habeck jo. PLoS One. 2013 Dec 2;8(12):e79775. doi: 10.1371/journal.pone.0079775. eCollection 2013. PLoS One. 2013. PMID: 24312450 Free PMC article. Clinical Trial.
69 results